Finder makes money from featured partners, but editorial opinions are our own. Advertiser disclosure

How to buy Emergent Biosolutions stock (EBS)

Buy Emergent Biosolutions stock in 5 easy steps, view past price performance and learn what’s ahead for the company.

Emergent Biosolutions is a drug manufacturers - specialty & generic business based in the US. Emergent Biosolutions shares (EBS) are listed on the NYSE and all prices are listed in US Dollars. Emergent Biosolutions employs 1,600 staff and has a trailing 12-month revenue of around $1.2 billion.

Our top picks for where to buy Emergent Biosolutions stock

Top pick for advanced traders

Go to site
Get up to $5,000 cash
  • Trade options, futures, options on futures, stocks, ETFs
  • $0 commission to close options
  • Pro-grade platform and risk analysis tools

Best for beginners

Go to site
Get up to $10,000 cash
  • Trade stocks, options, ETFs, mutual funds, alternative asset funds
  • $0 commission on stocks, ETFs and options, with no options contract fees
  • No-cost financial planning and automated investing

Our pick for cash sweep

Go to site
Advanced charts and trading tools
  • Trade stocks, ETFs and equity options without commission and $0 option contract fees
  • Earn up to 8.1% APY on your uninvested cash
  • Get a 1.5% match in cash on transferred assets up to $300 or up to 15 free fractional shares worth between $2 and $2,000

How to buy Emergent Biosolutions stock

  1. Choose a stock trading platform. Use our comparison table
  2. Open an account. Provide your personal information and sign up.
  3. Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
  4. Search for the stock name – EBS. Search for the stock by name or ticker symbol.
  5. Buy the stock. Place your order. It's that simple.

Buy Emergent Biosolutions stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.
1 - 4 of 4
Name Product Ratings Available asset types Stock trade fee Minimum deposit Cash sweep APY Signup bonus
Tastytrade
Finder Score: 4.4 / 5: ★★★★★
Tastytrade
★★★★★
Stocks, Options, ETFs, Cryptocurrency, Futures, Treasury Bills
$0
$0
N/A
Get $50-$5,000
Competitive, capped options commissions, with a reliable trading platform designed for serious traders.
SoFi Invest®
Finder Score: 4.2 / 5: ★★★★★
SoFi Invest®
★★★★★
Stocks, Options, Mutual funds, ETFs, Alternatives
$0
$0
0.02%
Get up to $10,000 cash
Commission-free stocks, ETFs and options, with no options per-contract fees. Plus, a no-cost robo-advisor and complimentary access to certified financial planners (CFPs).
Moomoo
Finder Score: 4.3 / 5: ★★★★★
Exclusive
Moomoo
★★★★★
Stocks, Options, ETFs
$0
$0
Up to 8.10%
Choose a 1.5% match or up to 15 free fractional shares
No commission stock, ETF and options trades, with $0 equity options contract fees, low margin rates and advanced trading tools.
Public.com
Finder Score: 4.2 / 5: ★★★★★
Public.com
★★★★★
Stocks, Bonds, Options, ETFs, Cryptocurrency, Alternatives, Treasury Bills, High-yield cash account
$0
$0
5.1%
Get up to $10,000 and transfer fees covered
Build a diversified portfolio of stocks, bonds, options, ETFs, crypto and alternative assets, with a high-yield cash account and options contract rebates.
loading

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Emergent Biosolutions stock price (NYSE: EBS)

Use our graph to track the performance of EBS stocks over time.

Emergent Biosolutions shares at a glance

Information last updated 2024-07-08.
Latest market close$10.65
52-week range$1.42 - $8.29
50-day moving average $5.29
200-day moving average $3.09
Wall St. target price$8.00
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-10.97

Is it a good time to buy Emergent Biosolutions stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Emergent Biosolutions price performance over time

Historical closes compared with the close of $10.65 from 2024-07-12

1 week (2024-07-05) 34.30%
1 month (2024-06-13) 76.32%
3 months (2024-04-12) 416.99%
6 months (2024-01-12) 419.51%
1 year (2023-07-13) 46.29%
2 years (2022-07-13) -66.19%
3 years (2021-07-13) 57.92
5 years (2019-07-12) 43.25

Is Emergent Biosolutions stock undervalued or overvalued?

Valuing Emergent Biosolutions stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Emergent Biosolutions's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Emergent Biosolutions's PEG ratio

Emergent Biosolutions's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.55. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Emergent Biosolutions's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Emergent Biosolutions's EBITDA

Emergent Biosolutions's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $100.2 million.

The EBITDA is a measure of a Emergent Biosolutions's overall financial performance and is widely used to measure a its profitability.

Emergent Biosolutions financials

Revenue TTM $1.2 billion
Operating margin TTM 13.25%
Gross profit TTM $290.1 million
Return on assets TTM -0.38%
Return on equity TTM -60.57%
Profit margin -47.69%
Book value $12.67
Market Capitalization $415.5 million

TTM: trailing 12 months

Emergent Biosolutions share dividends

We're not expecting Emergent Biosolutions to pay a dividend over the next 12 months.

Emergent Biosolutions share price volatility

Over the last 12 months, Emergent Biosolutions's shares have ranged in value from as little as $1.42 up to $8.2875. A popular way to gauge a stock's volatility is its "beta".

EBS.US volatility(beta: 1.62)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Emergent Biosolutions's is 1.621. This would suggest that Emergent Biosolutions's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Emergent Biosolutions overview

Emergent BioSolutions Inc. , a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It also provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; BAT for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Reactive Skin Decontamination Lotion Kit to remove or neutralize chemical warfare agents from the skin; Trobigard, a atropine sulfate obidoxime chloride auto-injector. In addition, the company is developing CGRD-001 for the treatment of poisoning by organophosphorus nerve agents or organophosphorus compounds; EBS-LASV to prevent Lassa fever; EBS-MARV to prevent Marburg virus disease; EBS-SUDV to prevent Sudan virus disease; Pan-Ebola mAbs for the treatment of ebola virus; SIAN Antidote for initial treatment of certain or suspected acute cyanide poisoning; UniFlu for immunity against influenza A and B viruses; and WEVEE-VLP for equine encephalitis virus infections. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.

Frequently asked questions

What percentage of Emergent Biosolutions is owned by insiders or institutions?
Currently 2.16% of Emergent Biosolutions shares are held by insiders and 69.849% by institutions.
How many people work for Emergent Biosolutions?
Latest data suggests 1,600 work at Emergent Biosolutions.
When does the fiscal year end for Emergent Biosolutions?
Emergent Biosolutions's fiscal year ends in December.
Where is Emergent Biosolutions based?
Emergent Biosolutions's address is: 400 Professional Drive, Gaithersburg, MD, United States, 20879
What is Emergent Biosolutions's ISIN number?
Emergent Biosolutions's international securities identification number is: US29089Q1058
What is Emergent Biosolutions's CUSIP number?
Emergent Biosolutions's Committee on Uniform Securities Identification Procedures number is: 29089Q105

More guides on Finder

Ask a Question

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Go to site